Multiplex Assay Kit for Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay)

TN-C; HXB; TN; GMEM; JI; Myotendinous antigen; Neuronectin; GP 150-225; Cytotactin; Hexabrachion; Glioma-associated-extracellular matrix antigen

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-93 89
EDTA plasma(n=5) 81-92 84
heparin plasma(n=5) 93-105 97
sodium citrate plasma(n=5) 80-94 85

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 87-105% 91-99% 87-94% 92-101%
EDTA plasma(n=5) 93-104% 91-98% 83-101% 93-101%
heparin plasma(n=5) 84-103% 92-101% 96-104% 98-105%
sodium citrate plasma(n=5) 78-101% 81-95% 78-95% 88-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:TNC) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Medical Principles and Practice An investigation of tenascin-C levels in rheumatic mitral stenosis and their response to percutaneous mitral balloon valvuloplasty Pubmed: 22889719
Tumor Biology Clinical significance of serum tenascin-c levels in epithelial ovarian cancer Springer: Source
Tumor Biology Clinical significance of serum tenascin-C levels in breast cancer Springer: Source
BioFactors Tenascin-C is increased in atherothrombotic stroke patients and has an anti-inflammatory effect in the human carotid artery. Pubmed:24823872
Connective Tissue Research Metabolic and cytoprotective effects of in vivo peri-patellar hyaluronic acid injections in cultured tenocytes Pubmed:25333747
K Role of Tenascin-C in the differential diagnosis of small round blue cell tumors Index.Php: Sdutfd
Life Sci A new predictor of mortality in hemodialysis patients; Tenascin-C PubMed: 26390818
Heart Research Biomarkers Score for Patients with Mitral Stenosis: A useful conjunction with Wilkins’s Score for Early Intervention Heartresearchopenjournal: Hroj5
Araştırmalar / Researches Pankreas Adenokarsinomunda Serum Tenascin-C Düzeyi Potansiyel Bir Biyobelirteç Midir? Cpdf:5C21620161255
Archives of Dermatological Research Increased tenascin C and DKK1 in vitiligo: possible role of fibroblasts in acral and non-acral disease Pubmed:29605863
Methods in Cell Biology How to detect and purify tenascin-C Pubmed:29310788
Scientific Reports Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion Pubmed: 31358880
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB975Hu02 Recombinant Tenascin C (TNC) Positive Control; Immunogen; SDS-PAGE; WB.
RPB975Hu01 Recombinant Tenascin C (TNC) Positive Control; Immunogen; SDS-PAGE; WB.
PAB975Hu01 Polyclonal Antibody to Tenascin C (TNC) WB; IHC; ICC; IP.
PAB975Hu02 Polyclonal Antibody to Tenascin C (TNC) WB; IHC; ICC; IP.
LAB975Hu71 Biotin-Linked Polyclonal Antibody to Tenascin C (TNC) WB; IHC; ICC.
MAB975Hu22 Monoclonal Antibody to Tenascin C (TNC) WB; IHC; ICC; IP.
MAB975Hu21 Monoclonal Antibody to Tenascin C (TNC) WB; IHC; ICC; IP.
MAB975Hu23 Monoclonal Antibody to Tenascin C (TNC) WB; IHC; ICC; IP.
MAB975Hu24 Monoclonal Antibody to Tenascin C (TNC) WB; IHC; ICC; IP.
SEB975Hu ELISA Kit for Tenascin C (TNC) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB975Hu Multiplex Assay Kit for Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.